Ledger. Australian venture funding, tracked

Government

U.S. Government

Coverage

Stories naming U.S. Government. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Funding announcement

ENA Respiratory Begins Part B Dosing

Melbourne biotech ENA Respiratory has begun dosing participants in the second part of its Phase IIa trial of INNA-051; its investor lineup, past government funding awards and BLUE KNIGHT alumni status are recapped.

News

ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations

Melbourne-based ENA Respiratory announced US patent allowances covering its TLR2 agonist platform and a COPD treatment method, strengthening IP protection for its INNA-051 nasal spray candidate now in Phase II testing.

News

ENA Respiratory Announces Dosing of First Participants in Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections

Melbourne biotech ENA Respiratory has begun dosing volunteers in a mid-stage trial of its INNA-051 antiviral spray, aimed at limiting common viral illnesses in at-risk groups.

2 deals

Manufacturing news briefs – stories you might have missed

A news roundup covering a government-backed hydrogen project for Telstra, a climate tech fund's first close, new appointments at a South Australian agency and a feed company, plus export approvals and science prizes.

Also @AuManufacturing

Something wrong? Tell us